Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Palliative Medicine in Practice
MENU
Shortcuts Submit an article Author Guidelines Reviewers 2023 Editorial Team Focus and Scope

open access

Vol 11, No 1 (2017)
Review paper
Published online: 2017-09-20
View PDF (Polish) Download PDF file View HTML (Polish)
Get Citation

The impact of palliative radiotherapy on quality of life of patients with advanced non-small cell lung cancer

Monika Rucińska1, Anna Sugajska1
Medycyna Paliatywna w Praktyce 2017;11(1):31-35.
Affiliations
  1. Department of Oncology, Faculty of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Poland

open access

Vol 11, No 1 (2017)
Review paper
Published online: 2017-09-20

Abstract

In the case of advanced stage of non-small cell lung cancer, patients usually are not suitable for radical oncological treatment given that curative intent and the goal of the treatment is to reduce symptoms and improve quality of life. Patients with thoracic symptoms seem to have worse quality of live. Palliative radiotherapy for patients with incurable non-small cell lung cancer can be used for improving thoracic symptoms and also symptoms from distant metastases. Radiotherapy — in various types of dose fractionation — can improve symptoms as well as quality of lives. It works better in patients with relatively good performance status. Contraindications to palliative radiotherapy include poor performance status, significant weakness and weight loss, and expected short-term survival.

Abstract

In the case of advanced stage of non-small cell lung cancer, patients usually are not suitable for radical oncological treatment given that curative intent and the goal of the treatment is to reduce symptoms and improve quality of life. Patients with thoracic symptoms seem to have worse quality of live. Palliative radiotherapy for patients with incurable non-small cell lung cancer can be used for improving thoracic symptoms and also symptoms from distant metastases. Radiotherapy — in various types of dose fractionation — can improve symptoms as well as quality of lives. It works better in patients with relatively good performance status. Contraindications to palliative radiotherapy include poor performance status, significant weakness and weight loss, and expected short-term survival.

Full Text:

View PDF (Polish) Download PDF file View HTML (Polish)
Get Citation

Keywords

non-small cell lung cancer, palliative radiotherapy, quality of life

About this article
Title

The impact of palliative radiotherapy on quality of life of patients with advanced non-small cell lung cancer

Journal

Palliative Medicine in Practice

Issue

Vol 11, No 1 (2017)

Article type

Review paper

Pages

31-35

Published online

2017-09-20

Page views

446

Article views/downloads

6375

Bibliographic record

Medycyna Paliatywna w Praktyce 2017;11(1):31-35.

Keywords

non-small cell lung cancer
palliative radiotherapy
quality of life

Authors

Monika Rucińska
Anna Sugajska

References (38)
  1. Delaney G, Barton M, Jacob S, et al. A model for decision making for the use of radiotherapy in lung cancer. Lancet Oncol. 2003; 4(2): 120–128.
    PubMed
  2. Jin CJ, Kong W, MacKillop W. Estimating the Need for Palliative Radiation Therapy for Lung Cancer: A Benchmarking Approach. Int J Radiat Oncol Biol Phys. 2017; 98(1): 240–241.
    CrossRefPubMed
  3. Kim M, Schrag D, Li L, et al. Predictors of radiation therapy (RT) use among Medicare patients with metastatic non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2015; 33(29_suppl): 124.
    CrossRef
  4. Cooley ME. Symptoms in adults with lung cancer. A systematic research review. J Pain Symptom Manage. 2000; 19(2): 137–153.
    PubMed
  5. LeBlanc TW, Nickolich M, Rushing CN, et al. What bothers lung cancer patients the most? A prospective, longitudinal electronic patient-reported outcomes study in advanced non-small cell lung cancer. Support Care Cancer. 2015; 23(12): 3455–3463.
    CrossRefPubMed
  6. Iyer S, Roughley A, Rider A, et al. The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study. Support Care Cancer. 2014; 22(1): 181–187.
    CrossRefPubMed
  7. Mohan A, Singh P, Singh S, et al. Quality of life in lung cancer patients: impact of baseline clinical profile and respiratory status. Eur J Cancer Care (Engl). 2007; 16(3): 268–276.
    CrossRefPubMed
  8. Salvo N, Hadi S, Napolskikh J, et al. Quality of life measurement in cancer patients receiving palliative radiotherapy for symptomatic lung cancer: a literature review. Curr Oncol. 2009; 16(2): 16–28.
    PubMed
  9. Morgensztern D, Ng SH, Gao F, et al. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol. 2010; 5(1): 29–33.
    CrossRefPubMed
  10. Macbeth FR, Abratt RP, Cho KH, et al. International Atomic Energy Agency. Lung cancer management in limited resource settings: guidelines for appropriate good care. Radiother Oncol. 2007; 82(2): 123–131.
    CrossRefPubMed
  11. Rodrigues G, Videtic GMM, Sur R, et al. Palliative thoracic radiotherapy in lung cancer: An American Society for Radiation Oncology evidence-based clinical practice guideline. Pract Radiat Oncol. 2011; 1(2): 60–71.
    CrossRefPubMed
  12. Report to the Medical Research Council by its Lung Working Party. Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomized trial of palliative radiotherapy with two fractions or ten fractions. Br J Cancer. 1991; 63: 265–270.
  13. Stevens R, Macbeth F, Toy E, et al. Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer. Cochrane Database Syst Rev. 2015; 1: CD002143.
    CrossRefPubMed
  14. Sundstrøm S, Bremnes R, Aasebø U, et al. Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial. J Clin Oncol. 2004; 22(5): 801–810.
    CrossRefPubMed
  15. Senkus-Konefka E, Dziadziuszko R, Bednaruk-Młyński E, et al. A prospective, randomised study to compare two palliative radiotherapy schedules for non-small-cell lung cancer (NSCLC). Br J Cancer. 2005; 92(6): 1038–1045.
    CrossRefPubMed
  16. Fairchild A, Harris K, Barnes E, et al. Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol. 2008; 26(24): 4001–4011.
    CrossRefPubMed
  17. Langendijk JA, ten Velde GP, Aaronson NK, et al. Quality of life after palliative radiotherapy in non-small cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys. 2000; 47(1): 149–155.
    PubMed
  18. Chow E, Harris K, Fan G, et al. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol. 2007; 25(11): 1423–1436.
    CrossRefPubMed
  19. Wu JSY, Wong RKS, Lloyd NS, et al. Supportive Care Guidelines Group of Cancer Care Ontario, Cancer Care Ontario Practice Guidelines Initiative Supportive Care Group. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys. 2003; 55(3): 594–605.
    PubMed
  20. Erridge SC, Gaze MN, Price A, et al. Symptom control and quality of life in people with lung cancer: a randomised trial of two palliative radiotherapy fractionation schedules. Clin Oncol (R Coll Radiol). 2005; 17(1): 61–67.
    PubMed
  21. Kramer GW, Wanders SL, Noordijk EdM, et al. Results of the Dutch National study of the palliative effect of irradiation using two different treatment schemes for non-small-cell lung cancer. J Clin Oncol. 2005; 23(13): 2962–2970.
    CrossRefPubMed
  22. Sundstrøm S, Bremnes RM, Brunsvig P, et al. Norwegian Lung Cancer Study Group. Palliative thoracic radiotherapy in locally advanced non-small cell lung cancer: can quality-of-life assessments help in selection of patients for short- or long-course radiotherapy? J Thorac Oncol. 2006; 1(8): 816–824.
    PubMed
  23. Bezjak A, Dixon P, Brundage M, et al. Clinical Trials Group of the National Cancer Institute of Canada. Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15). Int J Radiat Oncol Biol Phys. 2002; 54(3): 719–728.
    PubMed
  24. Mac Manus MP, Matthews JP, Wada M, et al. Unexpected long-term survival after low-dose palliative radiotherapy for non-small cell lung cancer. Cancer. 2006; 106(5): 1110–1116.
    CrossRefPubMed
  25. Murray PF, Illsley AL, Bond MG, et al. 115 Audit of high dose palliative radiotherapy survival outcomes in patients with non-small cell lung cancer (NSCLC) in Leeds between 1999 and 2009. Lung Cancer. 2011; 71: S40.
    CrossRef
  26. Lester JF, Macbeth FR, Toy E, et al. Palliative radiotherapy regimens for non-small cell lung cancer. Cochrane Database Syst Rev. 2006(4): CD002143.
    CrossRefPubMed
  27. Stevens W, Stevens G, Kolbe J, et al. Lung cancer in New Zealand: patterns of secondary care and implications for survival. J Thorac Oncol. 2007; 2(6): 481–493.
    CrossRefPubMed
  28. Vinod SK, O'Connell DL, Simonella L, et al. Gaps in optimal care for lung cancer. J Thorac Oncol. 2008; 3(8): 871–879.
    CrossRefPubMed
  29. Carrato A, Vergnenègre A, Thomas M, et al. Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study. Curr Med Res Opin. 2014; 30(3): 447–461.
    CrossRefPubMed
  30. Ball D, Thursfield V, Irving L, et al. Evaluation of the Simplified Comorbidity Score (Colinet) as a prognostic indicator for patients with lung cancer: a cancer registry study. Lung Cancer. 2013; 82(2): 358–361.
    CrossRefPubMed
  31. Brunelli A, Charloux A, Bolliger CT, et al. European Respiratory Society and European Society of Thoracic Surgeons joint task force on fitness for radical therapy. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J. 2009; 34(1): 17–41.
    CrossRefPubMed
  32. Giap F, Lau S, Gannavaparu BS, et al. Impact of Baseline Cachexia in Non-Small Cell Lung Cancer on Radiation Therapy Utilization and Survival. International Journal of Radiation Oncology*Biology*Physics. 2016; 96(2): E509.
    CrossRef
  33. Schaafsma J, Coy P. Response of global quality of life to high-dose palliative radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2000; 47(3): 691–701.
    PubMed
  34. Falk SJ, Girling DJ, White RJ, et al. Medical Research Council Lung Cancer Working Party. Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial. BMJ. 2002; 325(7362): 465.
    PubMed
  35. Sundstrøm S, Bremnes R, Brunsvig P, et al. Norwegian Lung Cancer Study Group. Immediate or delayed radiotherapy in advanced non-small cell lung cancer (NSCLC)? Data from a prospective randomised study. Radiother Oncol. 2005; 75(2): 141–148.
    PubMed
  36. Sloan JA, Zhao X, Novotny PJ, et al. Relationship between deficits in overall quality of life and non-small-cell lung cancer survival. J Clin Oncol. 2012; 30(13): 1498–1504.
    CrossRefPubMed
  37. Movsas B, Hu C, Sloan J, et al. Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial. JAMA Oncol. 2016; 2(3): 359–367.
    CrossRefPubMed
  38. Cella D. Quality of life considerations in patients with advanced lung cancer. Semin Oncol. 2004; 31(6 Suppl 11): 16–20.
    PubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73 , 80–180 Gdańsk, Poland

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl